Data from the Austrian Breast & Colorectal Cancer Study Group.

Gnant and his group said these data, regarded with demonstrated bone-protective effects of zoledronic acid previously, suggest that adding zoledronic acid to adjuvant endocrine therapy including ovarian function suppression should be considered for premenopausal ladies with ER-positive early breasts cancer.. Adjuvant zoledronic acid displays promise against ER-positive premenopausal breast cancer Researchers have got proven the continuing efficiency of treating sufferers with estrogen receptor-positive premenopausal breasts tumor with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression. Data from the Austrian Breast & Colorectal Cancer Study Group , reported at the 2011 CTRC-AACR San Antonio Breast Tumor Symposium, held Dec.Our study emphasizes the association of treatment unwanted effects with long-term outcomes. This novel finding is yet to be explained fully. The bottom line is that we have to be especially careful with patients who encounter significant toxicity during treatment. Conversely, we are able to reassure those patients who have a smooth ride through radiation therapy that they are likely to do above average.’.

Akonni receives NIJ grant to build up HCID system for SNP identification Akonni Biosystems, a molecular diagnostics business that develops, manufactures, and plans to advertise sophisticated genetic testing devices for diagnosing complex infectious and human diseases, today announced receipt of a almost $500,000 Phase III Grant from the National Institutes of Justice .